WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding Senate passage of the reauthorization of the Prescription Drug User Fee Act (PDUFA): “We are pleased that the House and Senate have voted to reauthorize PDUFA so this important legislation can finally be signed into law. The final package will help enhance and improve drug safety while providing the resources necessary for the Food and Drug Administration (FDA) to continue the efficient and comprehensive review of new drugs and biologics.
